BJM PHARMA CONSULTING LIMITEDActive

Company number 09576350Private limited companyIncorporated 2015
⚠ Accounts overdue. The next accounts were due on 28 Feb 2025 and had not been filed when the register was last updated.
⚠ Confirmation statement overdue. It was due on 20 May 2024.

Key figures

£45,845-1.2%
Net assets 2022/23
+271.0%
Average annual growth 2019/20–2022/23
020 k40 k60 k2019/202020/212021/222022/23

Like most small UK companies, BJM PHARMA CONSULTING LIMITED does not publish a profit and loss account in its latest accounts. The figures below come from the balance sheet.

Ratios

2022/23
Balance sheet structure
Current assetsFixed assetsLiabilitiesNet assets
050 k100 k150 k2019/202020/212021/222022/23
Filed accounts2019/20–2022/23
2019/202020/212021/222022/23
Total assets28,00667,937110,251144,637
Total liabilities35,06067,88963,40598,541
Net assets / total equity8981,28146,40145,845
Average number of employees1111

A dash (—) means no accounts were filed for that year or the item is not in the accounts; 0 is a zero stated in the accounts. Small companies usually file only a balance sheet, so the profit and loss account is often missing.

Summary: BJM PHARMA CONSULTING LIMITED

Company

BJM PHARMA CONSULTING LIMITED is a private limited company registered with Companies House under company number 09576350. It was incorporated on 6 May 2015. Its status is active. The registered office is in St. neots (PE19). Its nature of business (SIC 2007) is other professional, scientific and technical activities n.e.c. (74909).

Accounts

The latest accounts in the database are for 2022/23 (period ending 31 May 2023); the company files micro-entity accounts. Net assets were £45,845, down 1.2% on the previous year. Total assets were £144,637 and total liabilities £98,541. The company had an average of 1 employee. Figures are available for 4 financial years (2019/20–2022/23).

Control and charges

One person with significant control is registered.

Filing deadlines

The next accounts are due by 28 Feb 2025. The next confirmation statement is due by 20 May 2024.